{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088628","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.913962+00:00","generated_at":"2026-06-12T03:27:48.920040+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theriva Biologics Q2 2023: $34.2M cash, VCN-01 trial on track, FDA orphan drug","bullets":["Cash and equivalents $34.2M as of June 30, 2023, expected runway into Q4 2024.","VIRAGE Phase 2b trial (VCN-01 + chemo) enrollment on track to complete Q1 2024; US sites dosing initiated.","FDA granted orphan drug designation to VCN-01 for pancreatic cancer; previously for retinoblastoma.","Ramon Alemany, Ph.D., appointed SVP of Discovery; continues as chair of Scientific Advisory Board.","G&A expenses rose 80% to $2.7M; R&D expenses fell 10% to $3.1M vs Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088628","json":"https://secwatch.observer/filing/0001104659-23-088628.json","markdown":"https://secwatch.observer/filing/0001104659-23-088628.md","text":"https://secwatch.observer/filing/0001104659-23-088628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/0001104659-23-088628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/tm2322993d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:27:48.920040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82c7fd5e0d6ccb2f839df0337568a6d37b3a96ab","claim":"Theriva Biologics, Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/0001104659-23-088628-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}